eXmoor Pharma and Signadori Bio Forge Alliance to Advance Cutting-Edge Cell Therapy
A new transatlantic partnership is taking aim at one of the most pressing challenges in oncology – the treatment of solid tumours.
eXmoor Pharma, a UK-based integrated contract development and manufacturing organisation (CDMO) specialising in cell and gene therapy, has entered into a pivotal collaboration with Signadori Bio, a next-generation biotech developing gene-modified monocyte-derived macrophage therapies.
The agreement will see eXmoor guide Signadori’s lead cell therapy candidate through the complex journey from preclinical discovery to GMP-compliant manufacturing.
The candidate therapy is based on research originally developed at the prestigious Gustave Roussy Institute and is designed to overcome long-standing biological hurdles in treating solid cancers.
Bringing Translational Science to Life
At the heart of the collaboration is a full technology translation and development programme that will be executed at eXmoor’s advanced Cell and Gene Therapy Centre. This includes taking the therapy from bench to batch, with a focus on refining the manufacturing process to meet stringent GMP standards.
To further cement their support, eXmoor will also provide Signadori with an interim Head of Chemistry, Manufacturing and Controls (CMC), who will integrate into the biotech’s leadership team and help shape its technical development strategy during this critical phase.
Signadori’s platform is based on gene-modified monocyte-derived macrophages – immune cells that have shown potential in bypassing the traditional barriers that limit many cell therapies when targeting solid tumours.
The company believes this platform can offer a durable and effective response in cancer types where current therapies have limited efficacy.
Aligned for Success
While the financial terms of the agreement remain undisclosed, the two companies will operate under a shared decision-making framework.
This governance model has been specifically designed to align scientific, technical, and commercial activities with Signadori Bio’s broader investment strategy – a move that reflects the long-term vision of both parties.
The Chief Executive Officer of Signadori Bio and Partner at Sofinnova Partners explained that this collaboration represents a decisive step in their mission to bring next-generation monocyte-based therapies to patients with solid tumours. eXmoor’s expertise in early-stage process development and GMP translation is exactly what they need at this critical inflection point.
Echoing the sentiment, the Chief Executive Officer of eXmoor, commented that they are delighted to partner with Signadori Bio on such a promising and sophisticated cell therapy programme. Their approach to targeting solid tumours with gene-modified monocytes is not only innovative, but firmly rooted in translational science.
Conclusion: A New Chapter in Solid Tumour Treatment
As the field of cell and gene therapy continues to evolve, partnerships like this one between eXmoor and Signadori Bio signal a growing momentum toward tackling the complexities of solid tumours with precision and purpose.
By blending scientific innovation with manufacturing excellence, the two companies are paving the way for novel immunotherapies to reach patients who need them most.
With a shared commitment to scientific rigour and commercial readiness, this collaboration stands as a hopeful milestone in the journey to transform cancer care.
News Credits: eXmoor and Signadori Bio enter cell therapy partnership
Things you may also like:
- UCB’s BIMZELX Shows Sustained Three-Year Efficacy in Inflammatory Conditions
- Levicept Unveils Groundbreaking Phase 2 Data for LEVI-04
- Co-op Celebrates British Tomato Season with Fresh New Launches